Telitacicept found to ease primary Sjogren’s severity in Phase 2 clinical trial
Telitacicept, RemeGen’s experimental under-the-skin injection therapy, significantly reduced disease severity in adults with primary Sjögren’s syndrome (pSS), according to final data from a Phase 2 clinical trial. Results were detailed in the study “Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized,…